How Did AbbVie's Immunology Franchise Fare in Q3?

Zacks
Apri Zacks
How Did AbbVie's Immunology Franchise Fare in Q3?

AbbVie ABBV announced encouraging third-quarter 2026 results last month, which beat expectations for both earnings and sales. The company's immunology revenues increased 16.6% year over year on an operational basis to approximately $9.2 billion. The figure accounted for nearly 53% of total revenues.

Strong sales of its two blockbuster drugs, Rinvoq and Skyrizi, helped offset the continued erosion of legacy drug Humira and reinforced their importance as AbbVie's key long-term growth drivers.

Skyrizi sales jumped 22.9% year over year on an operational basis to $5.8 billion, while Rinvoq revenues increased 24.3% to $2.7 billion. Both drugs benefited from strong demand and market-share gains across their approved indications, particularly in inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's disease (CD).

In contrast, Humira sales declined 30.6% year over year to $683 million due to continued biosimilar competition.

ABBV Raises ’26 Outlook for Skyrizi & Rinvoq

Strong momentum across its immunology franchise also supported AbbVie's improved 2026 outlook. The company raised its sales forecasts for both drugs. It now expects Skyrizi sales of $21.8 billion and Rinvoq sales of approximately $10.3 billion. Combined, the two drugs are expected to deliver more than 20% growth in 2026. Overall immunology revenues are forecast at approximately $34.9 billion.

New indications are expected to provide further growth opportunities. Skyrizi recently received FDA approval for a subcutaneous induction regimen for CD, offering patients a more convenient treatment option. Management expects payer access to expand over approximately 60 days, with the benefits likely to become more visible in early 2027.

Meanwhile, Rinvoq is expanding its presence in dermatology, with commercialization for vitiligo and alopecia areata underway in Europe. U.S. regulatory decisions for both indications are anticipated over the coming months. AbbVie expects the two indications to generate nearly $2 billion in combined peak sales.

ABBV’s Competition in the Immunology Space

The immunology market is highly competitive, with major pharmaceutical companies vying for market share across several indications. A key competitor is Johnson & Johnson JNJ, which markets two major immunology drugs, Stelara and Tremfya. Both drugs are approved for multiple inflammatory conditions, including UC and CD. Following the entry of Stelara biosimilars in the United States in 2025, J&J is increasingly relying on Tremfya’s growth to offset declining Stelara sales and support its immunology franchise.

J&J is also expanding its immunology portfolio. Earlier in March, it secured approval for Icotyde, a once-daily oral drug for moderate-to-severe plaque psoriasis. While still in the early stages of launch, the drug poses a competitive threat to Skyrizi.

Eli Lilly LLY is another competitor expanding its presence in immunology through Omvoh. The drug received FDA approval for UC in October 2023 and for CD in January 2025. These approvals established the LLY drug as a competitor in both major forms of IBD, where AbbVie’s Skyrizi has been gaining traction.

ABBV Stock Performance, Valuation & Estimates

Year to date, shares of AbbVie have risen 29% compared with the industry’s 26% growth.

Zacks Investment Research
Image Source: Zacks Investment Research

From a valuation standpoint, AbbVie is trading at a slight discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 18.73 times forward earnings, lower than its industry’s average of 19.82 times.

Zacks Investment Research
Image Source: Zacks Investment Research

The bottom-line estimate per share for 2026 has remained consistent at $13.97, while the 2027 estimate has increased from $15.95 to $16.02 over the past 30 days.

Zacks Investment Research
Image Source: Zacks Investment Research

AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
AbbVie Inc. (ABBV): Free Stock Analysis Report
 
Johnson & Johnson (JNJ): Free Stock Analysis Report
 
Eli Lilly and Company (LLY): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research